|Dr. James A. Campbell Ph.D., MBA||MD, CEO & Director||300k||N/A||N/A|
|Ms. Melanie Jaye Leydin||Company Sec.||96k||N/A||44|
|Dr. Deanne Greenwood Ph.D., MBA, GAICD||VP of Bus. Devel. & Intellectual Property||N/A||N/A||N/A|
Patrys Limited, a biopharmaceutical company, develops products for the treatment of cancer in Australia. The company develops PAT-SM6, a natural human antibody that is in Phase I/IIa clinical trials used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers, such as multiple myeloma; and PAT-SC1, a clinical trial antibody that treats gastric cancer. It also develops PAT-LM1, a natural human antibody that is used for the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10, a lupus autoantibody that penetrates live cell nuclei by binding to DNA or its precursors outside of cells and then following it into cell nuclei through a nucleoside transporter. The company was founded in 2006 and is based in South Melbourne, Australia.
Patrys Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.